Home LiteratureArticle Details
PMID: 8431012 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid.

Antimicrobial agents and chemotherapy ·Vol. 37 ·No. 1 ·1993-01-00 ·Pages 14-8

Barry AL, Fuchs PC, Pfaller MA

Abstract

In in vitro studies we evaluated the susceptibilities of beta-lactamase-producing and -nonproducing, ampicillin-resistant strains of Haemophilus influenzae and compared them with those of ampicillin-susceptible strains. Ampicillin, amoxicillin-clavulanic acid, ceftibuten, cefaclor, cefuroxime, cefixime, and cefotaxime were evaluated by broth microdilution tests and disk diffusion tests. The disk diffusion tests accurately categorized beta-lactamase-producing strains and ampicillin-susceptible strains as being susceptible to the study drugs other than ampicillin. Ampicillin-resistant, beta-lactamase-nonproducing strains were relatively resistant to all seven study drugs, but the disk diffusion test did not always predict that resistance. The clinical relevance of the decreased susceptibility to various agents remains unclear, but to be conservative, all ampicillin-resistant, beta-lactamase-nonproducing strains might be assumed to be resistant to other beta-lactams. After excluding that small group of isolates, reliable susceptibility test results were obtained with lots of Haemophilus Test Medium that met quality assurance criteria.

MeSH Terms
Amoxicillin/pharmacology Amoxicillin-Potassium Clavulanate Combination Ampicillin Resistance/physiology Cephalosporins/pharmacology Clavulanic Acids/pharmacology Culture Media Drug Therapy, Combination/pharmacology Haemophilus influenzae/drug effects Microbial Sensitivity Tests beta-Lactamases/biosynthesis
Chemicals
Cephalosporins Clavulanic Acids Culture Media Amoxicillin-Potassium Clavulanate Combination Amoxicillin beta-Lactamases
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Barry A L
Clinical Microbiology Institute, Tualatin, Oregon 97062.
Fuchs P C
Pfaller M A
References (17)
17 references, click to expand
  1. Characterization of non-beta-lactamase-mediated ampicillin resistance in Haemophilus influenzae.
    Antimicrob Agents Chemother. 1984 Aug;26(2):235-44 PMID: 6333208
  2. Haemophilus influenzae ATCC 49766, an alternative quality control strain for monitoring broth microdilution susceptibility tests with selected beta-lactams.
    J Clin Microbiol. 1992 Aug;30(8):2033-7 PMID: 1500511
  3. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae.
    J Clin Microbiol. 1987 Nov;25(11):2105-13 PMID: 3500965
  4. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.
    Antimicrob Agents Chemother. 1988 Feb;32(2):180-5 PMID: 3259121
  5. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability and broth microdilution quality control guidelines.
    Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):802-7 PMID: 3145869
  6. Haemophilus influenzae: antibiotic susceptibility.
    Clin Microbiol Rev. 1988 Apr;1(2):218-27 PMID: 3069197
  7. In vitro activities and targets of three cephem antibiotics against Haemophilus influenzae.
    Antimicrob Agents Chemother. 1989 Nov;33(11):1878-82 PMID: 2610499
  8. Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group.
    J Clin Microbiol. 1990 Mar;28(3):605-7 PMID: 2182675
  9. Problems with current recommendations for susceptibility testing of Haemophilus influenzae.
    Antimicrob Agents Chemother. 1990 Aug;34(8):1480-4 PMID: 2221855
  10. Cefuroxime treatment failure of nontypable Haemophilus influenzae meningitis associated with alteration of penicillin-binding proteins.
    J Infect Dis. 1990 Nov;162(5):1118-23 PMID: 2230238
  11. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States.
    Antimicrob Agents Chemother. 1990 Nov;34(11):2075-80 PMID: 2127342
  12. False resistance results using 5 micrograms cefixime disks to test Haemophilus influenzae.
    Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):596-7 PMID: 1915406
  13. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella (Branhamella) catarrhalis isolated in the UK from sputa.
    J Antimicrob Chemother. 1991 Aug;28(2):249-59 PMID: 1778856
  14. Performance of Haemophilus Test Media prepared with 12 different lots of Mueller-Hinton agar from four manufacturers.
    J Clin Microbiol. 1992 May;30(5):1145-7 PMID: 1583112
  15. Investigation of ampicillin-intermediate strains of Haemophilus influenzae by using the disk diffusion procedure and current National Committee for Clinical Laboratory Standards guidelines.
    J Clin Microbiol. 1992 Jul;30(7):1674-7 PMID: 1629320
  16. Development of revised quality control limits for disk diffusion susceptibility tests of selected cephem antibiotics with Haemophilus influenzae and description of a new control strain.
    J Clin Microbiol. 1992 Aug;30(8):2029-32 PMID: 1500510
  17. Failure to detect ampicillin-resistant, non-beta-lactamase-producing Haemophilus influenzae by standard disk susceptibility testing.
    Antimicrob Agents Chemother. 1986 Aug;30(2):274-80 PMID: 3490217
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1993-01-00
Pages
14-8
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC187597
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]